In this free webinar, learn about the production process and drug substance specifications for oligonucleotide therapeutics. Attendees will learn about chemistry, manufacturing and control (CMC) Investigational Medicinal Product (IMP) considerations for oligonucleotide therapeutics. The featured speakers will discuss the critical quality attributes (CQAs) and critical process parameters (CPPs) in oligonucleotide drug product development. The speakers will also share guidance on setting and meeting specifications to ensure quality and compliance.
TORONTO, Aug. 12, 2024 /PRNewswire-PRWeb/ -- Guidance in navigating through the regulatory grey area
Oligonucleotide therapeutics are an emerging field with over a dozen new oligonucleotide-based drugs approved globally since 2016. The well-established chemical process for synthesizing oligonucleotides gives access to 'large small' molecules of sizes between 5000 and 20,000 Daltons and positions oligonucleotide therapeutics between small molecules and biologicals.
Assessing the quality and specifications is often a challenge in this regulatory grey area because the International Council for Harmonisation (ICH) guidelines consider this modality as a chemical entity while sharing properties with biologics.
Therefore, a thorough understanding of oligonucleotide's mechanism of action, safety aspects and the production process helps with informed decision-making for the chemistry, manufacturing and controls' (CMC) critical quality attributes (CQAs).
In this webinar, the expert speakers will share insights on oligonucleotide therapeutics as an emerging therapeutic modality and focus on their production processes, drug substance specifications, material properties and potential impurities. They will also explore CMC Investigational Medicinal Product (IMP) considerations specific to oligonucleotides, including the identification of CQAs and critical process parameters (CPPs) essential for drug development.
They will also discuss key manufacturing aspects, as well as stability and scalability concerns for oligonucleotide therapeutics, to ensure a thorough understanding of the production lifecycle. Moreover, this webinar will provide guidance on progressing into early-phase clinical studies and emphasize on how to set and meet specifications to maintain quality and comply with regulatory standards, thus ensuring a smooth transition from development to clinical evaluation.
Register for this webinar today to gain expert insights into the complex regulatory landscape of oligonucleotide therapeutics.
Join ICON, André Boltjes, PhD, Project Director CMC; Pascal van Tilburg, BSc, Senior Project Manager and SME in CMC; and Jasper Boonstra, PharmD, PhD, Qualified Person, for the live webinar on Wednesday, September 4, 2024, at 10am EDT (4pm CEST/EU-Central).
For more information, or to register for this event, visit Considerations for Oligonucleotide Therapeutics in CMC.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article